Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
November 2024 AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback